Bieber, ThomasThomasBieberSimpson, Eric LEric LSimpsonSilverberg, Jonathan IJonathan ISilverbergThaçi, DiamantDiamantThaçiPaul, CarleCarlePaulPink, Andrew EAndrew EPinkKataoka, YokoYokoKataokaCHIA-YU CHUDiBonaventura, MarcoMarcoDiBonaventuraRojo, RicardoRicardoRojoAntinew, JeremiasJeremiasAntinewIonita, IleanaIleanaIonitaSinclair, RodneyRodneySinclairForman, SethSethFormanZdybski, JacekJacekZdybskiBiswas, PinakiPinakiBiswasMalhotra, BimalBimalMalhotraZhang, FanFanZhangValdez, HernanHernanValdez2021-09-072021-09-07202100284793https://scholars.lib.ntu.edu.tw/handle/123456789/582410The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block interleukin-4 receptors are limited.en[SDGs]SDG3abrocitinib; dupilumab; placebo; abrocitinib; dupilumab; immunoglobulin A; interleukin 4 receptor alpha; Janus kinase 1; monoclonal antibody; placebo; protein kinase inhibitor; pyrimidine derivative; sulfonamide; adult; Article; atopic dermatitis; comparative effectiveness; controlled study; dose response; double blind procedure; drug dose comparison; drug safety; female; human; loading drug dose; major clinical study; male; nausea; phase 3 clinical trial; priority journal; prospective study; randomized controlled trial; skin pruritus; atopic dermatitis; blood; clinical trial; comparative study; multicenter study; oral drug administration; pruritus; severity of illness index; subcutaneous drug administration; Administration, Oral; Adult; Antibodies, Monoclonal, Humanized; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Immunoglobulin A; Injections, Subcutaneous; Interleukin-4 Receptor alpha Subunit; Janus Kinase 1; Male; Placebos; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Severity of Illness Index; SulfonamidesAbrocitinib versus Placebo or Dupilumab for Atopic Dermatitisjournal article10.1056/NEJMoa2019380337612072-s2.0-85103370979https://api.elsevier.com/content/abstract/scopus_id/85103370979